BMP signalling: agony and antagony in the family by Brazil, Derek P. et al.
BMP signalling: agony and antagony in the family
Brazil, D. P., Church, R. H., Surae, S., Godson, C., & Martin, F. (2015). BMP signalling: agony and antagony in
the family. Trends in Cell Biology, 25(5), 249-264. DOI: 10.1016/j.tcb.2014.12.004
Published in:
Trends in Cell Biology
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
 2014 Elsevier Ltd. All rights reserved. This article has a Creative Commons Attribution-NonCommercial-NoDerivs License
(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.





BMP signalling: Agony and Antagony in the family 3 
 4 
Derek P. Brazil1*#, Rachel H. Church1*, Satnam Surae2, Catherine Godson2 and Finian 5 
Martin2# 6 
1. Centre for Experimental Medicine, Queen’s University Belfast, BT12 6BA, Northern 7 
Ireland. 8 
2. UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland 9 
*These authors contributed equally to this manuscript 10 
#To whom correspondence should be addressed: d.brazil@qub.ac.uk; finian.martin@ucd.ie.  11 




Bone morphogenetic proteins, antagonist, miRNA, Gremlin, disease 14 
 15 
Abstract 16 
Bone morphogenetic proteins (BMPs) are secreted extracellular matrix-associated proteins 17 
that regulate a wide range of development processes, including limb and kidney formation. A 18 
critical element of BMP regulation is the presence of secreted antagonists that bind and 19 
inhibit BMP binding to their cognate Ser/Thr kinase receptors at the plasma membrane. 20 
Antagonists such as Noggin, Chordin, Gremlin (Grem1) and twisted gastrulation-1 (Twsg1) 21 
have been shown to inhibit BMP action in a range of different cell-types and developmental 22 
stage-specific contexts. Here, we review new developments in the field of BMP and BMP 23 
antagonist biology during mammalian development, and suggest strategies for targeting these 24 
proteins in human disease.  25 
Introduction  26 
The first bone morphogenetic protein (BMP) was discovered by Dr. Marshall Urist, an 27 
orthopaedic surgeon in UCLA, in the 1960s. These proteins were shown to trigger the 28 
formation of bone and cartilage from mesenchymal stem cells in culture [1]. Since then, more 29 
than 22 members of the BMP family have been identified, along with a smaller set of plasma 30 
membrane receptors that activate a well-defined canonical signalling pathway involving the 31 
Smad1/5/8 proteins. Today, it is clear that BMP signalling extends beyond bone and cartilage 32 
formation, and is involved in such diverse biological processes as stem cell and organ 33 
formation, muscle development, iron metabolism, vascular biology and cancer. In addition, it 34 
is increasingly appreciated that a counterbalance of BMP and TGFβ signalling exists in many 35 
physiological processes and disease states. In 2010, we published a review in this journal 36 
summarising, to the best of our ability, the “state of play” regarding BMP signalling. It is an 37 
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indication of the pace of progress in the BMP field that a new review updating readers on 38 
developments is warranted a mere four years later. The emerging data describing BMP-TGFβ 39 
counter-regulatory signalling will also be discussed herein.  40 
BMP signalling 41 
BMPs are secreted members of the transforming growth factor-beta (TGFβ) family of 42 
signalling molecules. Both secreted BMPs and their antagonists are thought to associate with 43 
the extracellular matrix, restricting their diffusion and action to neighbouring cells [2]. 44 
Glycosylation of these proteins likely affects their interaction with the ECM and their 45 
function [3]. A range of BMP ligands bind to type I receptors (BMPRI or activin-like kinase 46 
(ALK)-2, ALK3 or ALK6). This complex then binds to a type II receptor (BMPRII), which 47 
phosphorylates the type I receptor in the GS glycine-serine repeat domain [4, 5]. The 48 
activated type I receptor phosphorylates a set of Smad proteins called receptor-Smads (R-49 
Smad1/5/8), which bind to a nuclear Smad called Smad4. This complex accumulates in the 50 
nucleus, where it is recruited to transcriptional complexes to mediate BMP-dependent gene 51 
transcription (Fig. 1). Smad-response elements are present in BMP gene targets such as 52 
inhibitor of differentiation (Id 1-3) genes, SnoN, and inhibitory Smad6 [6-8], which mediate 53 
many of the downstream effects of BMP signalling.  54 
A similar pathway is utilized by TGFβ ligands, which engage a distinct set of membrane 55 
receptors, and involve Smad2/3 as the R-Smads that regulate TGFβ-mediated gene 56 
expression. Each level of the BMP pathway is tightly regulated, emphasising the critical 57 
nature of maintaining tight control of BMP signalling in cells and tissues. BMP ligands are 58 
synthesised and secreted as larger propeptides that are then cleaved by extracellular pro-59 
protein convertases such as Furin [9, 10]. Mature BMPs form dimers which interact with 60 
BMPRI/II receptors forming a hexameric complex (Fig. 1).  61 
4 
 
New data has identified additional membrane proteins that may regulate BMP signalling. 62 
Endoglin (CD105), a type I membrane glycoprotein, is a novel co-receptor for TGFβ1/BMP 63 
signalling [11]. Endoglin regulates BMP-9 and BMP-10 signalling via interaction with the 64 
ALK1/type I receptor, and TGFβ1 signalling via ALK5/type II TGFβ receptor binding [12]. 65 
Members of the repulsive guidance molecule (RGM) family of receptors have also been 66 
shown to be required for BMP, but not TGFβ signalling [13]. Receptors such as RGMa and 67 
DRAGON (RGMb) are required for BMP-2 and BMP-12 mediated gene expression, whereas 68 
Hemojuvelin (RGMc) is involved in regulating BMP-dependent iron homeostasis via 69 
hepcidin expression in liver [14]. Another co-receptor called Cripto interacts with the ALK4 70 
type I receptor for Nodal, a member of the TGFβ family [15].  71 
Both BMP (Smad1/5/8) and TGFβ (Smad2/3) signalling requires Smad complexes to 72 
transduce their signals to the nucleus. Anchor proteins such as Endofin recruit and present 73 
Smad1 proteins to the BMP receptors for phosphorylation, and also mediate receptor 74 
dephosphorylation via its protein phosphatase binding motif [16]. SARA (Smad anchor for 75 
receptor activation) regulates TGFβ1-mediated Smad2/3 phosphorylation in a similar manner 76 
[17]. Additional proteins such as ERBIN and C18ORF1 compete with SARA for binding to 77 
Smad2/3 to influence TGFβ1 signalling [18, 19]. Both Endofin and SARA bind to PI3K in 78 
the endosomes, and are regulated by EGFR signalling [20, 21]. Binding of SARA to RNF11 79 
as part of the ESCORT-0 complex also regulates lysosomal degradation of EGFR [21, 22].  80 
In contrast to rapid substrate phosphorylation observed with receptor tyrosine kinases 81 
engaged by growth factors such as insulin and epidermal growth factor, the kinetics of BMP-82 
mediated Smad1/5/8 phosphorylation are much slower [23]. One reason for this may be the 83 
competition between Smad1/5 and inhibitory Smad6 for binding to the type I receptor [24, 84 
25]. The methyltransferase PRMT1 methylates Smad6 on Arginine, leading to Smad6 85 
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dissociation from the type I receptor, thereby facilitating Smad1/5/8 phosphorylation and 86 
BMP signalling (Fig. 1, [23]). Similar repression of BMP signalling is facilitated by FK-87 
binding protein 12 (FKBP12), which binds to BMP type I receptors and inhibits their 88 
activation (Fig. 1 [26]). Both biochemical and crystal structure data analysing the interaction 89 
of ALK2 receptor with FKBP12 has provided critical insights into the protein complex, 90 
suggesting reasons for why the R206H ALK2 mutation decreases FKBP12 binding, and leads 91 
to overactive BMP signalling and heterotopic ossification [27, 28]. Interestingly, FK506, a 92 
drug that binds to FKBP12 was shown to relieve this inhibition and reverse dysfunctional 93 
BMP-2 signalling in models of pulmonary artery hypertension [26]. A new protein in the 94 
BMP pathway called protein associated with Smad1 (PAWS1) also binds to Smad1 and is 95 
phosphorylated by ALK3/BMPR1A [29]. PAWS1 is required for Smad4-independent BMP-2 96 
activation of ASNS and NEDD4 genes in PC3 prostate cancer cells [29].  97 
Recent findings are providing evidence for crosstalk between BMP and other pathways such 98 
as TGFβ, Wnt, and Hedgehog. The type III TGFβ receptor (TGFβR3, also known as 99 
betaglycan [30] is required for BMP-2 signalling in epicardial cells [31, 32]. Endoglin, 100 
another co-receptor for BMP/TGFβ proteins has been shown to regulate crosstalk of TGFβ1 101 
and fibronectin/αvβ1 integrin signalling in endothelial cells [33]. BMP pathways can engage 102 
Smad2 and Smad3 in embryonic cells and in invasive ovarian, prostate and breast cancer 103 
cells [34], while TGFβ1 can activate Smad1/5/8 phosphorylation in a range of epithelial cells, 104 
regulating breast cancer cell migration [35, 36]. Furthermore, TGFβALK5Smad3 105 
signalling potently inhibits BMP-induced gene transcription and cell invasion via the 106 
formation of a Smad3 and pSmad1/5 complex that binds to BMP-response elements, 107 
ultimately repressing BMP target gene transcription [37]. This finding suggests that Smad3 is 108 
not only critical for TGFβ-induced inhibition of BMP signalling, but also contributes to limit 109 
the transcriptional output in response to TGFβ [37].  110 
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Crosstalk between BMP and Wnt/β-catenin signalling has been identified in several cell 111 
types. Indeed, activation of Wnt3a or overexpression of β-catenin/TCF4 activated BMP-2 112 
expression in osteoblasts [38]. Also, BMP-2 induced osteoblast differentiation via the rapid 113 
generation of reactive oxygen species (ROS), linking BMP-2 to NADPH oxidase-4 (Nox4)-114 
generated ROS and osteoblast differentiation [39].  In addition, Dishevelled/Par1b can 115 
facilitate TGFβ1 signalling during Xenopus mesoderm development and in mammalian 116 
HEK293 cells [40]. Others demonstrated that BMP-2 mediated chemotaxis of mesenchymal 117 
C2C12 mouse myoblast cells occurs via PI3Kinase signalling, with BMPRII binding to the 118 
p55γ/p110α class 1a of the PI3Kinase family [41]. BMP-2 mediated generation of PIP3 119 
triggered recruitment of the LL5β protein, and was required for actin reorganisation and 120 
chemotaxis in these cells [41]. 121 
Negative regulation of BMP signalling 122 
BMP signalling is regulated on multiple levels in cells, including intracellularly by inhibitory 123 
Smads (Smad 6, 7), miRNAs, methylation and extracellularly by pseudoreceptors such as 124 
BMP and Activin Membrane Bound Inhibitor (BAMBI) and BMP antagonists including 125 
Grem1 (Fig. 1, [7, 8]). For example, expression of BAMBI in endothelial cells reduces non-126 
canonical TGFβ1-mediated Smad1/5 and ERK1/2 phosphorylation, resulting in the inhibition 127 
of angiogenesis [42]. Below, we discuss emerging mechanisms controlling BMP signalling.  128 
BMP Antagonists: new insights from crystal structures  129 
BMP signal transduction is closely regulated by a set of structurally diverse extra-cellular 130 
secreted protein antagonists, which bind BMPs with high and specific affinity and disrupt 131 
ternary receptor complex formation. These antagonists range in size from 170-250 amino 132 
acids for the DAN/Cerberus family (including Gremlin1, PRDC and Coco) to larger multi-133 
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domain proteins such as Chordin (948 aa) and Follistatin (344 aa). BMP antagonists are 134 
secreted in a pro-form and the leucine/valine rich signal sequence (20aa) is cleaved by 135 
proprotein convertases, revealing the N-terminus BMP-interacting domain [43].  136 
BMP-antagonist crystallography has provided new insights into the activity and nature of 137 
their molecular interactions [44-47]. Human BMP antagonists do not share significant 138 
sequence similarity overall (Fig 2); however, identity increases towards the C-terminus, also 139 
termed the cystine knot domain (or Von Willebrand type C domain). The cystine knot is a 140 
defining feature of BMP antagonists, and is formed by 6 cysteine residues: two pairs of 141 
intramolecular disulphide bonds that form a ring, and a third cysteine pair which bonds 142 
through the ring completing the knot. TGFβ family members have seven conserved cysteine 143 
residues, whereas BMP antagonists have 6 cysteine residues.  Other conserved structural 144 
features of the TGFβ family members are that of the wrist and knuckle epitopes [48]. The 145 
knuckle epitope is formed by four anti-parallel β-sheets and the wrist is formed by a four-turn 146 
alpha-helix at the region of dimerization. Two BMP monomers form an antiparallel dimer, 147 
covalently linked through a disulfide bond. Ternary co-crystal 3D structures of BMP-BMP-148 
receptor complexes show that type I receptors interact with the wrist motif and type II 149 
receptors interact with the knuckle region [49-51]. The BMP antagonists Noggin and Chordin 150 
have 4 additional amino acids, generating ten-membered rings. The disulphide bridges in the 151 
cysteine rings ensure a strict structural conformation of the antagonists by ensuring correct 152 
folding of the peptide, backbone stability and exposure of key hydrophobic residues [43, 48]. 153 
Two co-crystal structures of BMP-BMP antagonist vividly demonstrate the similarities and 154 
differences in antagonist binding. The first co-crystal, BMP-7 in complex with Noggin, 155 
reveals a butterfly structure (Fig. 3a). The structure also reveals that the Noggin dimer forms 156 
a two-fold axis of symmetry with a head-to-head conformation rather than the overlapping 157 
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antiparallel conformation of its BMP ligand [44].  The Noggin clip extends and interacts with 158 
both wrist and knuckle residues, thus obstructing the BMP ligand to type I and type II 159 
receptor binding [44]. The second co-crystal, BMP-2 in complex with von Willebrand type C 160 
(VWC1) domain of Crossveinless-2 (CV2), shows considerable similarity in the prevention 161 
of BMP receptor binding, with CV2 antagonist interactions occurring at both wrist and 162 
knuckle epitopes of BMP-2 (Fig. 3b). Sequence similarity in the clip regions of Noggin and 163 
CV2, however, is not significantly shared [47]. A third structure, Follistatin in complex with 164 
Activin, highlights further antagonistic diversity by blockade of type I and type II receptor 165 
binding sites by a peripheral clamp mechanism and not with clip domains as observed with 166 
Noggin and CV2 [52, 53]. 167 
The VWC1 domain of CV2 is responsible for binding BMPs and is not only found in 168 
Chordin family members, but has also been identified in a diverse range of other extracellular 169 
proteins [47]. This X-ray resolved co-complex structure reveals the interaction of the VWC1 170 
domain, but does not fully explain the intricacies of its binding. It still remains unclear as to 171 
how the linear peptide of the clip segment contributes strongly to the overall binding energy, 172 
yet is assumed to be highly flexible when unbound. A second structural ensemble of VWC1 173 
unbound to other proteins resolved by NMR revealed that the clip segment and a 30-residue 174 
subdomain termed SD1 of the VWC domain is preformed in its unbound state (Fig. 3c). The 175 
highly flexible nature of the clip segment exhibited strong affinity to BMP-2. The NMR 176 
structure showed that the N-terminal segment of the clip was flexible and disordered, whereas 177 
subdomain 1 exhibited a small and rigid three-stranded β sheet core. This rigidity contributed 178 
to the pre-defined orientation of the clip in a paperclip or hook-like architecture that brought 179 
the clip in close proximity to its final BMP binding site; therefore, likely lowering the overall 180 
binding energy cost and increasing affinity to the complex [54, 55]. 181 
9 
 
Further, a recently detailed set of data demonstrates that the DAN family of protein 182 
antagonists form highly stable non-covalent dimers [56]. The antagonists, Protein Related to 183 
Dan or Cerberus (PRDC, also known as Gremlin2) and DAN, form non-covalent 184 
homodimers that do not require the unpaired cysteine residue of the cystine knot [56]. PRDC 185 
and DAN dimers are highly stable, as they did not dissociate after treatment with DTT, 186 
heating to 100 oC, or incubation with 4M urea [56]. The crystal structure of PRDC/Gremlin2 187 
has also been resolved, and it shows that PRDC forms a non-covalent head-to-tail growth 188 
factor-like dimer with an extensive hydrogen bond network between monomers (Fig. 3d, 189 
[46]). Mutagenesis of PRDC identified residues belonging to the DAN domain on the convex 190 
surface, rather than the N-terminus that are critical for BMP binding affinity. An N-terminal 191 
latch mechanism for BMP binding was therefore proposed due to the observed flexibility and 192 
potential for conformational sampling of the N-terminal domain that exposes the DAN 193 
domain residues upon interaction with a BMP ligand [46].  194 
The diversity of structures already seen within the family of BMP antagonists provides 195 
mechanistic and functional information that contributes to our understanding of the finely 196 
tuned specificities and affinities for BMP antagonists to BMP ligands and, in turn, to BMP 197 
signal transduction.  The structures of many more cysteine knot domain containing proteins, 198 
BMP antagonists and BMP co-complexes, remain to be resolved, and this information will 199 
aid in the understanding of BMP antagonist-mediated regulation of BMP signalling in 200 
physiological and disease conditions. 201 
 202 
Interactions between BMP antagonists 203 
A complex choreography of interactions between BMP antagonists has recently been 204 
demonstrated. Noggin and Grem1 interact to maintain a BMP signalling-free zone in the 205 
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mouse embryo, which is required for Sonic hedgehog (Shh)-mediated induction of the 206 
sclerotome or early vertebrae [57]. Moreover, limb development requires the regulation of 207 
Grem1 and Fgf10 expression by HoxA and HoxD genes, further supporting a link between 208 
Grem1 signalling and Shh signalling [58]. Noggin and Grem1, but not Chordin, were shown 209 
to be important for BMP-4 mediated clathrin-dependent endocytosis in mouse endothelial 210 
cells [59]. Using fluorescently labelled BMP-2, BMP-2 was found to be internalised in HeLa 211 
cells via a clathrin-dependent pathway, with Noggin and Grem1 increasing BMP-2 uptake. In 212 
contrast, Chordin decreased BMP-2 uptake, suggesting BMP ligand and receptor interactions 213 
on the cell surface involve cooperative binding of BMP antagonists such as Noggin and 214 
Grem1, as well as other proteins such as the Endoglin CD105 co-receptor [60]. Another 215 
example of antagonist cooperation was recently demonstrated for the BMP modulators BMP 216 
endothelial cell precursor derived regulator (BMPER) and twisted gastrulation (Twsg1). 217 
BMPER is the human ortholog of crossveinless-2 found in Drosophila, and was shown to 218 
activate BMP-4 at low concentrations, but inhibit BMP-4 signalling at higher concentrations, 219 
in an endocytic trap-and-sink mechanism in mouse endothelial cells [59]. BMPER has also 220 
been implicated in endothelial cell biology and angiogenesis, where the BMP antagonist 221 
Twsg1, but not Noggin or Chordin, was found to increase HUVEC sprouting in vitro and 222 
endothelial cell growth in a Matrigel plug assay in vivo [61, 62]. Interestingly, these Twsg1-223 
dependent effects were inhibited by the addition of recombinant BMPER, suggesting a 224 
delicate equilibrium exists whereby Twsg1 and BMPER interact to control each other’s pro-225 
angiogenic activity in endothelial cells [61]. 226 
 227 
MicroRNA regulation in BMP signalling 228 
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There has been a dramatic increase in the identification of miRNAs that regulate BMP 229 
signalling (Table 1). Among these is miR-21, which has been detected in skin epidermis, 230 
specifically keratinocytes, and is highly expressed in hair follicle tumours [63]. miR-21 is a 231 
downstream target of BMP-4 in mouse keratinocytes, and treatment of these cells with BMP-232 
4 dramatically reduced miR-21 levels, an effect that was reversed by overexpression of the 233 
BMP antagonist Noggin [63]. Furthermore, miR-21 regulates two groups of BMP-4 target 234 
genes in keratinocytes that are involved in tumour suppression and cell differentiation.  In 235 
addition, BMP-4 downregulates the miR302~367 cluster in a Smad1/5 dependent manner in 236 
human primary pulmonary artery smooth muscle cells (PASMCs) [64]. BMPRII was found 237 
to be the target of miR302, and therefore inhibition of miR-302 by BMP-4 increases BMP-4 238 
signalling by stabilizing the BMPRII transcript [64]. Also, miR-656 represses the expression 239 
of BMPR1A in U87 glioma cells and inhibits glioma tumorigenesis [65]. Similarly, BMP-2 240 
mediated glioma growth was inhibited by lentiviral miR-656 expression in mice suggesting a 241 
tumour suppressor role for miR-656 [65]. MiR-130a also targets BMP type I receptors, in this 242 
case ALK2 in liver cells [66]. The levels of miR-130a are increased by iron deficiency, which 243 
leads to a decrease in BMP-6/Smad1/5 signalling. As a result, levels of hepcidin, the main 244 
iron regulatory hormone in the body, are reduced, leading to increased iron availability in the 245 
circulation [66].  miR-22 has been identified as a master regulator of BMP-7/6 in the kidney 246 
[67], where BMP-7/6 have been proposed to act as anti-fibrotic BMPs in chronic diseases of 247 
the kidney, lung and other tissues (e.g. [68]). miR-22 deletion reduces the severity of kidney 248 
injury induced by unilateral ureteral obstruction (UUO), with higher levels of both BMP-7 249 
and BMP-6 evident in miR-22-/- kidneys post-UUO [67]. A concomitant increase in 250 
BMPRIb levels and pSmad1/5/8 phosphorylation was also observed in miR-22-/- kidneys, 251 
with miR-22 binding sites identified in the 3’ untranslated region of BMP-7, 6 and BMPRIb 252 
[67]. Interestingly, miR-22 is itself a transcriptional target of BMP-7/6 signalling, with 253 
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several BMP response elements identified in the miR-22 promoter. This study identifies miR-254 
22 as a key regulator of kidney fibrosis, and suggests that an auto-feedback loop likely exists 255 
between BMP-7/6 and miR-22 in the normal kidney and regulates kidney physiology (Table 256 
1). 257 
As well as inhibiting the expression of BMPs and their membrane receptors, some miRs have 258 
been shown to target BMP antagonists. Noggin expression is repressed by miR-200c/141 in 259 
dental epithelial-like cells through transcriptional upregulation of miR-200c by Pitx2, which 260 
binds to promoter elements in the miR200c/141 cluster to control the development of mouse 261 
incisors [69]. Similar to miR-22, expression of miR-200c is regulated by BMP signalling, 262 
creating a negative feedback loop during tooth development [69]. Noggin3 expression is also 263 
controlled by miR-92a during cartilage and skeletal formation in Zebrafish [70]. Degradation 264 
of Noggin3 mRNA by miR-92a allows sustained BMP activity, which facilitates the survival 265 
and differentiation of chondrocytes [70]. Therefore, miR-92a and Noggin3 act in opposition 266 
to regulate BMP signalling during cartilage formation. In addition, miR-27b  directly targets 267 
the 3’ UTR of Grem1, and regulates Grem1-mediated gene expression changes in lung 268 
fibroblast cells, adding to the efforts to identify the as-yet-undefined role of miR-27b in 269 
fibrosis in vivo (Table 1, [71]).  270 
BMP antagonist signalling: focus on Gremlin1 271 
Grem1 has been well characterised as a secreted antagonist that regulates BMP action during 272 
development, controlling limb and kidney formation [73, 74]. New data have identified that 273 
Grem1 may have its own intrinsic signalling capability, independent of BMP antagonism 274 
(Fig. 5). In kidney studies, treatment of mouse mesangial cells with high glucose or 275 
conditioned medium containing Grem1 increased the expression of TGFβ1, CTGF and 276 
collagen type IV proteins associated with diabetes-induced damage to the glomerulus [121]. 277 
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Increased ERK1/2 phosphorylation was also observed in cells treated with Grem1, likely 278 
contributing to the enhanced mesangial cell proliferation observed under these conditions 279 
[121]. Exposure of human tubular epithelial cells (HK-2) to recombinant Grem1 caused 280 
phenotypic changes resembling epithelial-mesenchymal transition (EMT), with decreased E-281 
cadherin and increased myofibroblast markers such as vimentin and alpha smooth muscle 282 
actin (α-SMA) [122]. Grem1 had a similar profibrotic effect on renal fibroblasts, and 283 
silencing of Grem1 using siRNA prevented TGFβ1-induced EMT in HK-2 cells [122]. 284 
Grem1 has also been implicated in aristolochic acid-induced EMT and fibrosis [123].  285 
Several reports have identified novel non-BMP binding partners for Grem1. Grem1 can bind 286 
to Slit proteins to negatively regulate monocyte chemotaxis [124], and Grem1 can bind to 287 
fibrillin microfibrils in mesothelioma cells ([89]). A novel function for Grem1 is as a 288 
proangiogenic regulator where Grem1 can bind to VEGFR2 in a similar manner to that of 289 
VEGF in endothelial cells and can increase angiogenesis in vitro and in vivo [125]. This 290 
effect involves Grem1 binding to heparin and heparin sulphate proteoglycans on the surface 291 
of endothelial cells [126]. In addition, the engagement of αvβ3 integrins and the formation of 292 
αvβ3/VEGFR2 complexes are involved in Grem1-mediated angiogenesis [127]. The 293 
identification of Grem1 as a novel proangiogenic factor has implications in highly 294 
vascularised tumours and also in the field of endothelial cell biology. Recently the effect of 295 
Grem1 on human umbilical cord haematopoietic progenitors was explored, showing that the 296 
balance between Grem1 and BMP-2 and BMP-4 are involved in atherosclerotic plaques [128, 297 
129] . The phosphorylation of ERK1/2 is a downstream effect of Grem1 activation (e.g. [89, 298 
121]. Consistently, embryonic fibroblasts isolated from grem1-/- mice display reduced ERK 299 
phosphorylation compared to wild-type cells [130]. The BMP antagonist Gremlin2 (also 300 
called PRDC) has recently been shown to activate JNK signalling in embryonic stem cells 301 
during their differentiation into atrial cardiomyocytes [131]. 302 
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BMP and BMP antagonist signalling in development and disease 303 
The critical role of BMPs and their secreted antagonists in development and disease has been 304 
highlighted by the identification of dramatic phenotypes in mice lacking either BMPs or 305 
BMP antagonists (e.g. [72-76]). In the adult, it is increasingly appreciated that subversion of 306 
the equilibrium between the activities of BMP agonists and antagonists may underlie several 307 
pathologies including cancer, skeletal disorders and fibrosis of kidney, lung, liver, eye and 308 
heart. In addition, a counterbalance between BMP and TGFβ signalling exists in many tissues 309 
and disease contexts, whereby BMP signalling can act to “dampen” TGFβ signalling and vice 310 
versa (Fig. 4). In addition, BMP antagonists can act to amplify TGFβ signalling via inhibition 311 
of BMP signalling. Some recent examples of this are discussed below. 312 
Cancer  313 
BMPs and their antagonists play a critical role in stem and progenitor cell biology regulating 314 
the balance between differentiation and expansion respectively. In basal cell carcinoma, 315 
cancer-associated fibroblasts secrete the BMP antagonists follistatin and Grem1 [77]. These 316 
antagonists act in a paracrine fashion to facilitate self-renewal and continued proliferation of 317 
cancer cells, overwhelming BMP control of proliferation. In human basal cell carcinoma 318 
Grem1 expression was detectable in the tumour stroma but not in adjacent normal skin [77]. 319 
Recently, Grem1 was identified at the cancer invasion front, suggesting a role for this BMP 320 
antagonist in colorecetal cancer metastasis [78, 79]. Grem1 has also been identified as a 321 
prognostic marker of pancreatic neuroendocrine tumours, and correlates with increased 322 
angiogenesis and increased patient survival [80]. 323 
In melanoma, autocrine inhibition of cell proliferation by BMP-7 was attenuated by the BMP 324 
antagonist Noggin which promotes tumour progression [81]. The BMP antagonist Coco has 325 
also been demonstrated to play an important role in promoting proliferation of breast cancer 326 
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cells which have extravasated to the lung. Initially, local production of BMPs limits the 327 
proliferative capacity of these cells, which is overcome by the antagonistic activities of Coco. 328 
Importantly, the Coco expression signature has been shown to predict metastatic relapse to 329 
the lung in humans [82]. In contrast to this oncogenic role, inhibition of BMP signalling has 330 
been shown to suppress tumour growth and lung metastases in a murine model of breast 331 
cancer [83]. 332 
Within a tumour microenvironment, progression versus stasis may be dependent on cancer 333 
stem cell (CSC) mediated-self renewal or differentiation. BMP-2 regulates CSC-induced 334 
differentiation, suggestive of a net tumour suppressive role. Increased BMP-2 expression, but 335 
conversely, decreased BMP-2 activity was detected in CSCs isolated from glioblastomas 336 
[84]. This apparent paradox was explained by the enhanced secretion of Grem1 from CSCs, 337 
leading to inhibition of BMP-2 and increased p21 signalling [84, 85]. TGFβ1, in contrast, 338 
acts to maintain cancer stem cells in their undifferentiated state, and antibodies such as 1D11 339 
which target the TGFβ1 receptor have been shown to have efficacy in certain cancer subtypes 340 
(Fig. 4, [86, 87]).  341 
The CSC example above provides a useful example of the opposing actions of BMPs versus 342 
TGFβ1 to maintain homeostasis in different cells and tissues, which is an important theme 343 
emerging from the field. The crosstalk in BMP and TGFβ1 signalling has been discussed 344 
above, and other examples of BMP versus TGFβ1 signalling in tissue fibrosis and EMT and 345 
regulation by KCP-1 will be discussed below. A further example of BMP versus TGFβ 346 
balance involves the formation of muscle mass, where BMP-mediated signalling increases 347 
muscle mass, whereas myostatin, a member of the TGFβ/activin family negatively regulates 348 
this process (summarised in Fig. 4,  [88]).  349 
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Grem1 is highly expressed in mesothelioma tumour samples and primary mesothelioma cells. 350 
The high expression of Grem1 along with Slug, a transcriptional regular of E-cadherin, is 351 
connected with resistance to paclitaxel-induced cell death. Interestingly, silencing Grem1 352 
with siRNA inhibits cell proliferation and induces a reduction in cancer cell survival upon 353 
treatment with paclitaxel [89]. It was suggested that upregulation of fibrillin-2 provides a 354 
mechanism for Grem1 localisation to the extracellular matrix of the tumour (Fig. 5, [89]). 355 
Grem1 has been shown to bind to A549 lung cancer and HeLa cells in a BMP and VEGFR2 356 
independent manner [90]. Additionally, stably transfected A549 cells expressing Grem1 357 
increased tumour growth in vivo compared to mock transfected A549 cells, further 358 
suggesting that Grem1 may potentiate tumour growth (Fig. 5, [90]). 359 
 360 
Diabetes and Diabetic Retinopathy 361 
The dual BMP/Wnt antagonist Sostdc1 (also known as USAG-1) plays a role in pancreatic 362 
islet function. Levels of Sostdc1 were upregulated in islets from non-immune-mediated lean 363 
diabetic mice, and a subset of sostdc1-/- mice displayed enhanced insulin secretion and 364 
improved glucose tolerance after high-fat diet feeding compared to wild-type controls [91]. 365 
Interestingly, sostdc1-/- islets displayed significant reductions in Grem1 and CTGF 366 
expression, suggesting a complex interplay between the BMP modulators may exist in islets 367 
[91].  368 
Both diabetic nephropathy (DN) and retinopathy (DR) are microvascular complications of 369 
diabetes that develop in a significant number of diabetic patients. The underlying 370 
mechanisms involved in DR overlap with DN (see below). For example, exposure of retinal 371 
pericytes to high glucose increased Grem1 expression [92]. A potential role of Grem1 in 372 
proliferative vitreoretinopathy was also identified [93]. Transition of lens epithelia to 373 
mesenchymal cells and subsequent matrix accumulation is a feature of glaucoma [94]. Grem1 374 
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expression is increased in the glaucomatous trabecular meshwork cells and tissues and 375 
elevates intraocular pressure (IOP) [95]. In this context, Grem1 potentiates the effects of 376 
TGFβ matrix accumulation by attenuating BMP-4 signalling [95]. Furthermore, treatment of 377 
human trabecular meshwork cells with recombinant Grem1 induced ECM cross-linking lysyl 378 
oxidase (LOX) genes [96]. Grem1-mediated LOX gene induction involved both canonical 379 
(Smad) and non-canonical (JNK and p38 MAPK) signalling [96]. These data provide 380 
important insights into the potential contribution of Grem1 to increased intraocular pressure 381 
and glaucoma.   382 
Kidney disease 383 
Human Greml1 was first described in the context of experimental models of diabetic 384 
nephropathy (DN), a chronic complication of diabetes associated with glomerulosclerosis and 385 
tubulointerstitial fibrosis [97, 98]. Further investigation revealed that i) increased expression 386 
of Grem1 correlated with DN disease severity [99], ii) a Grem1 gene variant was associated 387 
with DN in patients and iii) grem1+/- mice were protected from early stage sequelae of DN 388 
[100]. siRNA-mediated targetting of Grem1 in the kidney also resulted in protection from DN 389 
in a murine model, linked to increased BMP-7 activity [101] Consistently, tubular epithelial 390 
overexpression of Grem1 exacerbated injury in response to folic acid-induced nephropathy 391 
[102]. In podocytes, Grem1 aggravates injury to cells grown in high glucose, and triggers a 392 
downregulation of nephrin and synaptopodin, key proteins of the glomerular basement 393 
membrane [103]. siRNA targetting of Grem1 rescued podocytes from high glucose-induced 394 
injury, supporting the hypothesis that Grem1 is a primary driver of renal cell damage during 395 
diabetes. This study suggests that this effect may be due to Grem1 inhibition of BMP 396 
signalling, leading to increased TGFβ1-mediated Smad2/3 phosphorylation [103].  397 
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Mice lacking Grem1 die shortly after birth due to the absence of kidneys, arising from a 398 
failure of ureteric bud outgrowth and GDNF/Wnt11 signalling during embryogenesis [73]. 399 
The allelic reduction of BMP-4 reverses this phenotype, and grem1−/−;BMP-4+/− mice 400 
develop normal kidneys as a result of a corrected “volume” of BMP signalling [104]. 401 
Similarly, the complete inactivation of BMP-7 restored ureteric bud outgrowth in grem1-/- 402 
mice, but did not restore normal kidney formation due to the loss of nephrogenic progenitor 403 
cells [105]. BMP-6 null mice manifest increased tubulointerstitial damage and renal fibrosis 404 
in response to unilateral ureteric obstruction compared to wild-type mice [106], identifying 405 
BMP-6 as another major regulator of renal fibrosis in the kidney [107].  406 
Further evidence for the importance of BMP agonist antagonist interactions in the mature 407 
kidney was provided by investigations of USAG-1 and Twsg-1. USAG-1 is the most 408 
abundant BMP antagonist expressed in the kidney and negatively regulates renoprotection by 409 
BMP-7 in numerous experimental models of glomerular and tubular injury [108]. Using a 410 
model of Alport syndrome (a hereditary form of nephritis), the deletion of USAG-1 411 
attenuated renal injury likely due to enhanced BMP-7 suppression of MMP-12 expression 412 
[109]. Interestingly, the ability of the lipid lowering agent simvastatin to ameliorate renal 413 
fibrosis has been linked to the repression of USAG-1 expression, thus enhancing anti-fibrotic 414 
BMP-7 signalling [110]. This USAG-1/BMP-7 axis has also been implicated in 415 
supernumerary incisor formation, with enhanced BMP-7 signalling in usag1-/- mice thought 416 
to drive this process [111]. Podocyte injury and loss is considered an important factor in 417 
initiating glomerular injury and proteinuria in DN and other renal conditions. Twisted 418 
Gastrulation (Twsg1) has been shown to be the dominant BMP antagonist secreted by 419 
podocytes, and acts in synergy with chordin or chordin-like molecules to modulate BMP 420 
activity [112]. Twsg1 antagonises BMP-7-induced podocyte differentiation, and is expressed 421 
in damaged glomeruli of a mouse model of podocyte injury and proteinuria. Consistently, 422 
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twsg1-/-mice were relatively resistant to podocyte injury suggesting that future 423 
pharmacological strategies targetting Twsg1 may be a useful avenue for the treatment of 424 
renal disease [112].   425 
Disorders of the liver 426 
Gremlin, along with follistatin, was identified as a marker of liver fibrosis using gene array 427 
screens of hepatic stellate cells induced to undergo transdifferentiation into myofibroblasts 428 
[113]. Upregulation of Grem1 was also identified in chronic hepatitis, liver cirrhosis and liver 429 
cancer as a result of hepatitis C, with Grem1 expression correlating with the stage of liver 430 
cancer in the patients [114]. Using a CCl4 mouse model of liver fibrosis, it was shown that 431 
treatment with BMP-7 could attenuate the severity of damage and improve liver function 432 
[115]. Levels of Grem1 were increased in the fibrotic liver, and treatment with BMP-7 further 433 
increased Grem1 expression, which is difficult to rectify given the current dogma regarding 434 
the pro-fibrotic role of Grem1 and the anti-fibrotic role of BMP-7. Furthermore, adenoviral 435 
delivery of BMP-7 suppressed CCl4 induced liver fibrosis in mice [116]. Many of these 436 
effects are likely related to changes in TGFβ1 expression, which is thought to be the major 437 
cytokine driving liver fibrosis and regulating liver carcinogenesis [117].  438 
Miscellaneous 439 
BMPs and their antagonists such as BMP-4, BMP-7, Grem1 and Twsg1, are involved in 440 
lymphopoiesis, where they are expressed in specific compartments in the bone marrow and 441 
thymus [118]. Surprisingly, the conditional knockout mice lacking BMP-7 or Twsg1 in 442 
haematopoietic cells had no effect on B and T cell number [118]. However, Twsg1-deficient 443 
B cells demonstrated hyperresponsiveness after B-cell receptor stimulation [119]. Conditional 444 
knockout of Grem1 in the ovaries of female mice altered early folliculogenesis, but did not 445 
affect overall fertility compared to wild-type mice [120].  446 
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All of the data above point to a critical role for BMP and BMP antagonist signalling in 447 
serious human diseases such as cancer, diabetic kidney disease and liver fibrosis. It is clear 448 
that a delicate balance between BMP and TGFβ signalling exists in many cells, and 449 
perturbations in this balance as a result of changes in BMP antagonists such as Grem1 can 450 
contribute to the development of human disease. The following section will highlight recent 451 
efforts to develop new treatments for diseases where an imbalance of BMP/TGFβ signalling 452 
is implicated.   453 
Therapeutic potential of BMP and BMP antagonists in human disease 454 
Targeting BMPs in human disease 455 
Pharmacological targeting of BMP action has long been a focus point for many. Given their 456 
key role in bone formation, the delivery of recombinant human BMPs has been developed to 457 
accelerate impaired fracture healing in the long bones and spinal cord (reviewed in [132, 458 
133]). Recombinant human BMP-2 (available as InFuse® from Medtronic), and rhBMP-7 459 
(available as OP-1 from Olympus) are sometimes used as adjunct therapies for the treatment 460 
of non-union fractures [134]. However, the therapeutic benefit of these rhBMPs is hampered 461 
by the high costs of treatment, a shortage of robust data from double blind clinical trials, and 462 
a range of adverse effects in patients [132, 135].  463 
BMP-7 signalling has been a key target for reversing fibrosis or scar formation in the kidney, 464 
heart, lung and other organs. A wealth of in vitro and in vivo evidence suggests that BMP-7 465 
possesses anti-fibrotic activity, due to its ability to reverse TGFβ1-mediated fibrosis in many 466 
tissues. For example, in the mouse heart, subcutaneous delivery of rhBMP-7 reduced cardiac 467 
fibrosis as a result of pressure overload, and also decreased vascular calcification due to 468 
excess vitamin D levels [136, 137]. Intracolonically delivered adeno-associated virus-469 
mediated delivery of rhBMP-7 (AAV-BMP-7) reduced the severity of acute ulcerative colitis 470 
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in rats [138]. Oral administration of AAV-rhBMP-7 suppressed CCl4-hepatic fibrosis in mice 471 
[116]. Delivery of AAV-rhBMP-7 also reduced the infarct size in a stroke model of middle 472 
cerebral artery occlusion in mice [139]. A gene therapy approach using gold nanoparticles 473 
containing the BMP-7 gene inhibited fibrosis in a rabbit model of corneal damage [140].  474 
In the kidney, administration of rhBMP-7 has been shown to attenuate the severity of renal 475 
fibrosis induced by a range of insults including ischaemic injury [141], nephrotoxic serum 476 
nephritis [142] and diabetic nephropathy (DN) [143]. Despites its potential benefits, rhBMP-477 
7 displayed a lack of efficacy in treating lung, skin or kidney fibrosis [144, 145]; however, 478 
several groups are still developing therapeutic agents based on BMP-7 and/or activation of 479 
the ALK3 BMPRIA receptor. 480 
A peptide mimetic of BMP-7 called THR123 was recently developed. THR123 is a 16-amino 481 
acid cyclic peptide corresponding to the finger 2 region of BMP-7 and was designed based on 482 
the predicted BMP-ALK3 binding regions using TGF-β2 and BMP-7 crystal structures [146]. 483 
THR123 binds to the ALK3 receptor in vitro, and administration of THR123 reverses kidney 484 
fibrosis in a range of mouse models including nephrotoxic serum nephritis, diabetic 485 
nephropathy and the col4a3 knockout mouse model of Alport syndrome [146]. However, 486 
some questions have been raised regarding the ability of THR123 to activate the ALK3 487 
receptor, and whether a hydrophyllic peptide containing a C-terminal sequence that would 488 
favour digestion in the GI tract would reach therapeutic doses after oral administration [147].  489 
Other small molecule activators of BMP signalling have been identified through a library 490 
screen of bioactive compounds using a BMP responsive luciferase assay in human cervical 491 
cancer cells [148]. Two lead compounds, both members of the flavonoid chalcone family, 492 
were identified and shown to have both canonical (Smad1/5/8 phosphorylation) and non-493 
canonical (ERK phosphorylation) activity [148]. In vivo, these chalcone molecules induced 494 
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ventralisation of Zebrafish embryos, a hallmark of BMP activation during development 495 
[148]. Screening the Spectrum collection of drug compounds, natural products and bioactive 496 
molecules (2320 compounds in total) using BMP-responsive luciferase activity identified 497 
tilorone as a strong inducer of BMP activity. Importantly, tilorone decreased the degree of 498 
fibrosis in a mouse model of silica-induced lung fibrosis [149]. Increased pSmad1 499 
phosphorylation was detected in the lungs of these mice, with concomitant reductions in 500 
TGFβ1 signalling [149]. These data, along with previous results using THR123 indicate that 501 
inducers of BMP-7 signalling may have therapeutic benefit for the treatment of fibrosis in the 502 
lung and kidney. Other strategies aimed at boosting BMP signalling in disease have focussed 503 
on the kielin/chordin-like protein-1 (KCP-1). KCP-1 (also called Crim2) binds to BMP-7 and 504 
enhances its engagement with the BMPRI receptor [150]. Kcp1-/- mice developed severe 505 
renal fibrosis in response to unilateral ureteric obstruction (UUO) and folic acid-induced 506 
nephropathy [150]. Conversely, KCP-1 binds to TGFβ1 and inhibits it interaction with its 507 
receptor [151]. Indeed, transgenic mice overexpressing KCP-1 in the proximal tubules 508 
displayed attenuated fibrosis in the kidney, and revealed that pSmad1 levels (BMP target) 509 
were increased, while pSmad3 (TGFβ1 target) was reduced (Fig. 4, [152]).  510 
TGFβ1 is the primary pro-fibrotic cytokine that mediates tissue fibrosis, and strategies aimed 511 
at inhibiting TGFβ1 signalling (such as through BMP-7 and its analogues) have been pursued 512 
by many. Recently the administration of lipoxin A4 (LXA4), an anti-inflammatory lipid 513 
mediators that inhibits injury in the kidney and other tissues (e.g. [153-155]), have proven 514 
effective in reducing renal fibrosis in response to unilateral ureteric obstruction (UUO) in 515 
mice. The mechanism of LXA4 was a reduction in TGFβ1-mediated signalling and a 516 
corresponding decrease in extracellular matrix-associated gene expression in kidney 517 
epithelial cells [153]. The anti-fibrotic effect of LXA4 involves the induction of let7c 518 
miRNA, which targets several elements of the TGFβ1 signalling pathway [156]. MiRNA-519 
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200b was also identified as a repressor of TGFβ1-induced epithelial-mesenchymal transition 520 
(EMT) via targeting of the E-box binding transcription factors ZEB1 and ZEB2 [157].  521 
Targetting BMP Antagonists in human disease 522 
While the therapeutic benefit of boosting BMP signalling is evident in fibrosis of the kidney 523 
and lung, other diseases, as a result of excessive BMP signalling, may benefit from BMP 524 
inhibition. An inhibitor of BMP signalling called Dorsomorphin was identified in a screen for 525 
molecules that disrupt dorsoventral patterning in Zebrafish embryos [158]. Dorsomorphin 526 
blocked pSmad1/5/8 phosphorylation via inhibition of ALK2, ALK3 and ALK6 receptor 527 
signalling [158]. Dorsomorphin also provided evidence for an essential physiological role for 528 
hepatic BMP signalling and iron metabolism [158]. Dorsomorphin and its derivatives (e.g. 529 
LDN-193189) reduced the severity of fibrodysplasia ossificans progressive (FOP) in mouse 530 
models, by inhibiting of BMP signalling [158, 159]. Moreover, Dorsomorphin induced the 531 
myocardial differentiation of mouse embryonic stem cells via inhibition of BMP signalling 532 
[160]. The ability of Dorsomorphin to disrupt dorsoventral patterning in zebrafish, due to 533 
“off-target” anti-angiogenic effects on the VEGF type 2 receptor (Flk1/KDR) [161]. Further 534 
structure activity studies identified a potent and selective inhibitor of ALK2 called DMH1 535 
that disrupted zebrafish dorsoventral patterning but not vascular development [161]. DMH1 536 
induced the formation of beating cardiomyocytes from mouse embryonic stem cells, 537 
highlighting a novel role for BMP inhibition during cardiomyogenesis [162]. In addition, a 538 
novel class of BMPRI ALK2 inhibitors, based on the structure of Dorsomorphin have been 539 
identified and the lead compound, K02288 inhibits BMP-4-mediated Smad1/5/8 540 
phosphorylation at nanomolar concentrations in C2C12 cells. In addition, K02288 induced 541 
dorsalization of Zebrafish embryos, similar to that seen with Dorsomorphin [158, 163].  542 
Targeting Grem1 in human disease 543 
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Given the wealth of data implicating increased Grem1 in diseases of the kidney, lung, liver 544 
and in cancer, an obvious strategy is to design therapeutic inhibitors of Grem1 to treat these 545 
conditions. Data supporting this hypothesis was provided by reports showing that grem1+/- 546 
mice developed less severe early symptoms of DN compared to wild-type [100]. In addition, 547 
siRNA-mediated targeting of Grem1 reduced the severity of kidney injury [101]. Furthermore 548 
Grem1 may be a potential target for lung disease, in particular idiopathic pulmonary fibrosis 549 
(IPF) and pulmonary artery hypertension (PAH). Grem1 is expressed in macrophages and the 550 
alveolar epithelial lining of the normal lung [164], and in the interstitium of lungs with IPF 551 
[164].  Transient overexpression of Grem1 in rat lungs using adenovirus resulted in alveolar 552 
epithelial cell activation and thickening, along with an increase in inflammatory cell 553 
infiltration [165]. Collagen deposition and accumulation of α-SMA myofibroblasts were 554 
observed in fibroblastic foci. Interestingly, the BMP-4 precursor protein co-555 
immunoprecipitated with Grem1, suggesting that Grem1 binding to BMP-4 causing the 556 
reduction in Smad1/5/8 phosphorylation [165]. In parallel with Grem1 activation, FGF-10, an 557 
epithelium protectant, was elevated in fibrotic lung epithelial cells, whereas FGF-7 and 9 558 
were decreased, suggesting that a Grem-BMP-FGF-10 loop may exist in the fibrotic lung 559 
[165]. 560 
It has previously been shown that mutations in the BMPRII are implicated in heritable PAH 561 
[166]. Levels of Grem1 are also increased in lung biopsies from PAH patients, likely as a 562 
result of hypoxia-induced upregulation in pulmonary endothelial cells [167, 168]. Similar to 563 
DN in the kidney, grem1 haploinsufficiency protects against hypoxia-induced increases in 564 
vascular resistance in mice [167]. A novel strategy to target Grem1 using a therapeutic 565 
monoclonal antibody was recently developed and tested in a mouse model of PAH. Mice 566 
treated with the Grem1 targeting antibody showed a reduction in pulmonary vascular 567 
remodelling and right ventricular pathology [169]. In addition, a Grem1 antibody reduced 568 
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cancer cell migration and invasiveness, independent of BMP and VEGFR2 binding [90]. 569 
These data are an important proof-of-principle demonstrating that therapeutic targeting of 570 
Grem1 may provide new avenues to improve the treatment of cancer, as well as fibrotic 571 
conditions of the lung and kidney and other organs (summarised in Fig. 5).   572 
Concluding remarks 573 
This review has attempted to summarise the numerous, recent findings regarding BMP 574 
signalling. Despite a number of important advances in deciphering the signalling modalities 575 
of BMPs and their antagonists, many challenges remain. More experiments are needed to 195 576 
antagonists during developmental processes, physiology and disease. A clear pattern of 577 
crosstalk and competing effects between BMPs and TGFβ is emerging in different tissues. 578 
The identification of cross-interactions between BMP antagonists such as Noggin and Grem1 579 
presents additional complexities in elucidating BMP signalling [170]. There is a strong 580 
possibility that tissue and disease context may determine the specific interactions of BMPs 581 
and their antagonists, as well as with TGFβ. Identifying these interactions will increase the 582 
opportunities for pharmacological intervention to modify BMP/BMP antagonist signalling, 583 
similar to the Grem1 targeting approach developed in pulmonary artery hypertension. We 584 
eagerly anticipate future developments in this field, and emerging BMP-targeting therapies 585 
that will improve disease treatment and patient outcomes. 586 
 587 
Figure Legends 588 
Figure 1. Complex regulation of BMP signalling. BMPs are processed by proprotein 589 
peptidases to generate mature dimers which then bind to two copies of the type I and type II 590 
BMP receptors, generating a heterohexameric complex. Binding of BMP homodimers to their 591 
cognate receptors leads to phosphorylation of the type I receptor by the type II receptor in the 592 
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GS domain. Activated BMP receptors then phosphorylate Smad1/5/8 proteins which dimerise 593 
with Smad4 and accumulate in the nucleus, where they mediate changes in BMP-regulated 594 
gene expression. Regulation of this pathway occurs extracellularly via the binding of 595 
extracellular antagonists such as Grem1 and Noggin (1), or in the plasma membrane via the 596 
action of pseudoreceptors such as BAMBI (2). In addition, inhibitory constraints on receptor-597 
mediated Smad1/5/8 phosphorylation occur via FKBP12 binding and inhibitory Smad6 598 
binding, which is relieved by the action of a PRMT1 methyltransferase (3). Additional 599 
regulation of BMP signalling occurs via cytosolic phosphatases and ubiquitin ligases such as 600 
Smurf (4), and via miRNA (5) and methylation (6) mediated control of BMP-mediated gene 601 
expression. 602 
Figure 2. Sequence homology of BMP antagonists. (a) Multiple sequence alignment of the 603 
cysteine knot regions of BMP antagonists. Red boxes indicate highly conserved cysteine 604 
residues. (b) Phenogram of BMP antagonists based on sequence similarity.  605 
Figure 3. Structures of BMPs and BMP antagonists. Cartoon representation of protein 606 
structure of (a) BMP-7 in complex with Noggin (PDB entry 1M4U), (b) BMP-2 in complex 607 
with VWC1 domain of Crossveinless-2 (PDB entry 3BK3), (c) PRDC dimer (PDB entry 608 
4JPH) and (d) NMR resolved unbound structure of VWC1 of CV2 (PDB entry 2MBK) 609 
superimposed to X-ray resolved bound structure of VWC1 of CV2 in complex with BMP-2 610 
(PDB entry 3BK3). All protein structure representations generated using PyMol (DeLano 611 
2002). 612 
Figure 4. BMP and TGFβ signalling play counteregulatory roles in some cases of 613 
physiology and disease. Some examples of the counteracting regulation of cellular responses 614 
by BMP-7 and TGFβ are shown. BMP-7 signalling acts to inhibit fibrosis in kidney and lung, 615 
whereas TGFβ is well established as a primary fibrotic driver in many tissues. BMP-7 616 
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signalling is potentiated by the binding of Kielin/Chordin-like protein-1 (KCP-1), which 617 
facilitates BMP-7 binding to its cognate receptors. In contrast, KCP-1 binds to TGFβ and 618 
prevents it binding to its receptors, thus inhibiting its signalling. BMP-7 and TGFβ signalling 619 
are also counter balanced in cancer stem cell differentiation and the regulation of muscle 620 
mass (see text for details). 621 
Figure 5. Grem1 signalling occurs via diverse mechanisms in cells. (a) Grem1 dimers bind 622 
to BMP dimers and prevent engagement of BMP receptors, preventing BMP signalling and 623 
gene expression (see text for details). (b) Grem1 binds to VEGFR2 in endothelial cells and 624 
promotes angiogenesis. Heparin sulphate proteoglycans (HSPGs) and αvβ3 integrins are 625 
required for this response [125, 126]. (c) Grem1 has been shown, via an unidentified 626 
mechanism, to activate cancer cell invasion and proliferation. This effect occurs 627 
independently of BMP VEGFR2 signalling [90]. (e) Grem1 can bind to Slit1 and 2 and 628 
facilitates their binding to the Robo receptor, leading to inhibition of monocyte chemotaxis 629 
[124]. (f) Grem1 associates with fibrillin microfibrils and triggers Slug expression, leading to 630 
EMT and mesothelioma cell survival [89].  (g) Grem1 can bind to and sequester BMP-4 631 
precursor protein, preventing mature BMP-4 secretion [171].  632 
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Table 1. Summary of miRNAs regulating BMP signalling. 654 
miRNA Target Biological Function/Consequence Reference 
 




BMP-2 Enriched miRNA in undifferentiated hMSCs which 
directly represses BMP-2 expression and 
subsequent BMP-2 mediated osteogenesis, 
thereby negatively regulating osteogenic lineage 
commitment 




BMP-7 Inhibits BMP-7-mediated osteogenesis, 
suppressing osteoblast differentiation and 





miR-208 Ets1 Regulates BMP-2 stimulated preosteoblast 
differentiation in a mouse cell line 





Negatively regulate BMP-2 mediated osteogenic 
differentiation in vitro 
Wu T, 2012 [175] 
miR-155 SOCS1 Induced by TNF-α. Targets SOCS1. Plays a role in 
modulating TNF-α inhibition of BMP induced 
osteoblast differentiation of MC3T3-E1 cells 
Wu T, 2012 [176] 
 
 




BMPR1A Inhibits Smad1/5/8 phosphorylation and Id1 
expression, supresses angiogenesis in vitro and in 
vivo, impairs HT-29 colon cancer cell xengraft 
growth in vivo  
Xiao F, 2014 [177] 
miR-656 BMPR1A Downreguated in glioma cell lines and tissues. 
Overexpression of miR-656 suppresses glioma 
cell proliferation, neurosphere formation, migration 
and invasion, as well as tumour growth in vivo 
Guo M, 2014 [65] 
miR-365 SHC1 
BAX 
Induces gemcitabine resistance in pancreatic cells, 
Downregulation of apoptosis-promoting genes and 
upregulation of invasion-promoting genes in 
pancreatic cancer cells. 




Downregulated in breast cancer. BMP-6 treatment 
of MDA-MB-231 cells results in upregulation of 
miR-192. BMP-6 caused inhibition of cell 
proliferation in vitro and decreased tumour growth 
in vivo. 







Upregulated in cancer stroma, may contribute to 
cancer progression 













Required for skeletal muscle differentiation and 
regeneration in vivo 





miR-30b BMP-7 Inhibits BMP-7, is involved in EMT induced by 
methylglyoxal in peritoneal mesothelial cells in rat 
model 
Liu H, 2014 [183] 
miR-135a BMPR1A 
BMPR1B 
Overexpression of miR-135a inhibits transcription 
of BMPR1A and BMPR1B. May play a role in 
regulating tooth formation via regulation of BMP 
signalling 
Kim EJ, 2014 
[184] 
miR-26a Smad1 Overexpression of miR-26a inhibits pulmonary 
surfactant synthesis in type II epithelial cells from 
pulmonary alveolus 




miR-26a Smad1 Regulates angiogenesis in vitro and in vivo. 
Inhibits BMP/Smad signalling pathway. Targeting 
miR-26a, triggered angiogenesis and decreased 
myocardial infarct size in a mouse model 
Icli B, 2013 [186] 
miR-21 BMPRII 
RhoB 
Hypoxia and BMPRII signalling upregulate miR-21 
in vitro in human pulmonary artery endothelial 
cells. miR-21 expression is increased in pulmonary 
hypertension 







miR-21 expressed in epidermis and skin follicle 
epithelium. Downstream target of BMP-4 in mouse 
keratinocytes e.g. ID1-3, Msx-2 
 
 







Maintaining pluripotency and self-renewal of 
human embryonic stem cells by targeting BMP 
inhibitors. Modulation of TGF-β, BMP signalling 
during neural induction 
Lipchina I, 2011 
[188] 
miR-24 Trb3 miR-24 targets Trb3, decreasing Smad expression 
and BMP signalling 
PDGF inhibits BMP mediated changes in 
pulmonary smooth muscle cells and also induces 
expression of miR-24 





Inhibits BMP-7 and -6 but also induced by BMP-7 
and -6 via a negative feedback loop. 
BMP-7 and -6 expression are increased in kidneys 
of miR-22 null mice. Targeted deletion of miR-22 
attenuated renal fibrosis in UUO model 
Long J, 2013 [67] 
miR-27b Grem1 Regulates Grem1-mediated fibrotic gene 
expression changes in vitro 
Graham JR, 2014 
[71] 
miR-92a Noggin3 Targets Noggin3. Maintains BMP signalling during 
pharyngeal cartilage formation 
Ning G, 2013 [70] 
miR-302-
367 
BMPRII  BMP signalling downregulates miR 302-367 
expression. Overexpression of miR-302 
downregulates BMP signalling 







Table 2. Targetting BMP signalling in human disease. 661 
 662 
Disease Target Novel 
treatment 
Rationale Outcome Reference 
Kidney 
 






fibrosis in a range 






Grem1 Grem1 siRNA  Grem1 contributes 




















in vitro  
 
Reversed severe 
PAH in vivo 
Spiekerkoetter 






















Reduced degree of 































































iron and transferrin 
saturation in vivo 
Andriopoulos 







































ossification in vivo 




in patients with 
fibrodysplasia 
ossificans 





rhGDF-5 has been 
shown to have 
osteoinductive 
properties and a 
rhGDF-5/β-TCP 





2- to 3-fold higher 
amount of new 












Cancer Grem1 Grem1 
antibody 
Grem1  Reduced cancer 
cell migration and 
invasiveness in a 
BMP and VEGFR2 
independent 
manner 



























not deplete splenic 
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